<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1807245603
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Concentia
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHYLPHENIDATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        78.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Laboratorios Liconsa S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Laboratorios Liconsa S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Exeltis Healthcare S.L 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Concentia is used to treat &lsquo;attention deficit hyperactivity disorder&rsquo; (ADHD).<br />&bull; In children and young people between the ages of 6 and 18.<br />&bull; Only after trying treatments which do not involve medicines. Such as counselling and behavioural therapy.<br />Concentia is not for use as a treatment for ADHD in children under 6 years of age or for the initiation of treatment in adults. When treatment was started at a younger age, it might be appropriate to continue taking Concentia when you become an adult. Your doctor will advise you about this.<br />&nbsp;</p><p><strong>How it works</strong><br />Concentia improves the activity of certain parts of the brain which are under-active. The medicine can help improve attention (attention span), concentration and reduce impulsive behaviour. The medicine is given as part of a treatment programme, which usually includes:<br />&bull; psychological<br />&bull; educational and<br />&bull; social therapy.<br />It is prescribed only by doctors who have experience in children or young people&#39;s behaviour problems. Although there is no cure for ADHD, it can be managed using treatment programmes.</p><p><br /><strong>About ADHD</strong><br />Children and young people with ADHD find it:<br />&bull; hard to sit still and<br />&bull; hard to concentrate.<br />It is not their fault that they cannot do these things.<br />Many children and young people struggle to do these things. However, with ADHD they can cause problems with everyday life. Children and young people with ADHD may have difficulty learning and doing homework. They find it hard to behave well at home, at school or in other places. ADHD does not affect the intelligence of a child or young person.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Concentia if:<br />&bull; you are allergic to methylphenidate or any of the other ingredients of this medicine (listed in section 6)<br />&bull; you have a thyroid problem<br />&bull; you have increased pressure in your eye (glaucoma)<br />&bull; you have a tumour of your adrenal gland (phaeochromocytoma)<br />&bull; you have an eating problem when you do not feel hungry or want to eat - such as &lsquo;anorexia nervosa&rsquo;<br />&bull; you have very high blood pressure or narrowing of the blood vessels, which can cause pain in the arms and legs<br />&bull; you have ever had heart problems - such as a heart attack, uneven heartbeat, pain and discomfort in the chest, heart failure, heart disease or were born with a heart problem<br />&bull; you have had a problem with the blood vessels in your brain - such as a stroke, swelling and weakening of part of a blood vessel (aneurysm), narrow or blocked blood vessels, or inflammation of the blood vessels (vasculitis)<br />&bull; you are currently taking or have taken within the last 14 days an antidepressant (known as a monoamine oxidase inhibitor)- see &lsquo;Other medicines and Concentia&rsquo;<br />&bull; you have mental health problems such as:<br />- a &lsquo;psychopathic&rsquo; or &lsquo;borderline personality&rsquo; problem<br />- abnormal thoughts or visions or an illness called &lsquo;schizophrenia&rsquo;<br />- signs of a severe mood problem like:<br />▪ feeling like killing yourself<br />▪ severe depression, where you feel very sad, worthless and hopeless<br />▪ mania, where you feel unusually excitable, over-active, and un- inhibited.<br />Do not take methylphenidate if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before you take methylphenidate. This is because methylphenidate can make these problems worse.</p><p><br /><strong>Warnings and precautions</strong><br />Talk to your doctor before taking Concentia if:<br />&bull; you have liver or kidney problems<br />&bull; you have a problem with swallowing or swallowing whole tablets<br />&bull; you have a narrowing or blockage of your gut or food-pipe<br />&bull; you have had fits (seizures, convulsions, epilepsy) or any abnormal brain scans (EEGs)<br />&bull; you have ever abused or been dependent on alcohol, prescription medicines or street drugs<br />&bull; you are a girl and have started your periods (see the &lsquo;Pregnancy, breast-feeding and contraception&rsquo; section below)<br />&bull; you have hard-to-control, repeated twitching of any parts of the body or you repeat sounds and words<br />&bull; you have high blood pressure<br />&bull; you have a heart problem which is not in the &lsquo;Do not take&rsquo; section above<br />&bull; you have a mental health problem which is not in the &lsquo;Do not take&rsquo; section above.<br />Other mental health problems include:<br />- mood swings (from being manic to being depressed - called &lsquo;bipolar disorder&rsquo;)<br />- feeling aggressive or hostile<br />- seeing, hearing or feeling things that are not there (hallucinations)<br />- believing things that are not true (delusions)<br />- feeling unusually suspicious (paranoia) - feeling agitated, anxious or tense - feeling depressed or guilty.<br />Tell your doctor or pharmacist if any of the above apply to you before starting treatment. This is because methylphenidate can make these problems worse. Your doctor will want to monitor how the medicine affects you.<br />During treatment, boys and adolescents may unexpectedly experience prolonged erections. This may be painful and can occur at any time. It is important to contact your doctor straight away if your erection lasts for longer than 2 hours, particularly if this is painful.</p><p><br /><strong>Checks that your doctor will make before you start taking Concentia</strong><br />These checks are to decide if methylphenidate is the correct medicine for you. Your doctor will talk to you about:<br />&bull; any other medicines you are taking<br />&bull; whether there is any family history of sudden unexplained death<br />&bull; any other medical problems (such as heart problems) you or your family may have<br />&bull; how you are feeling, such as feeling high or low, having strange thoughts or if you have had any of these feelings in the past<br />&bull; whether there is a family history of &lsquo;tics&rsquo; (hard-to-control, repeated twitching of any parts of the body or repeating sounds and words)<br />&bull; any mental health or behaviour problems you or other family members have ever had. Your doctor will discuss whether you are at risk of having mood swings (from being manic to being depressed - called &lsquo;bipolar disorder&rsquo;). They will check your mental health history, and check if any of your family have a history of suicide, bipolar disorder or depression.<br />It is important that you provide as much information as you can. This will help your doctor decide if methylphenidate is the correct medicine for you. Your doctor may decide that other medical tests are needed before you start taking this medicine.</p><p><br /><strong>Other medicines and Concentia</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines. Do not take methylphenidate if you:<br />&bull; are taking a medicine called a &lsquo;monoamine oxidase inhibitor&rsquo; (MAOI) used for depression, or have<br />taken an MAOI in the last 14 days. Taking an MAOI with methylphenidate may cause a sudden increase in your blood pressure.<br />Tell your doctor or pharmacist if you or your child is taking any of the following medicines for depression or anxiety:<br />&bull; tricyclic antidepressant<br />&bull; selective serotonin reuptake inhibitor (SSRI)<br />&bull; serotonin and norepinephrine reuptake inhibitor&rsquo; (SNRI).<br />Taking methylphenidate with these types of medicine could cause a life-threatening increase of &lsquo;serotonin&rsquo; in the brain (serotonin syndrome), which may lead to feeling confused or restless,<br />sweating, shivering, muscle jerks or fast heart beat. If you or your child develops these side effects, see a doctor straight away.<br />If you are taking other medicines, methylphenidate may affect how well they work or may cause side effects. If you are taking any of the following medicines, check with your doctor or pharmacist before taking methylphenidate:<br />&bull; medicines for severe mental health problems<br />&bull; medicines for Parkinson&rsquo;s disease (such as levodopa)<br />&bull; medicines for epilepsy<br />&bull; medicines used to reduce or increase blood pressure<br />&bull; some cough and cold remedies which contain medicines that can affect blood pressure. It is important to check with your pharmacist when you buy any of these products<br />&bull; medicines that thin the blood to prevent blood clots.<br />If you are in any doubt about whether any medicines you are taking are included in the list above, ask your doctor or pharmacist before taking methylphenidate.<br />Please tell you doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><br /><strong>Having an operation</strong><br />Tell your doctor if you are going to have an operation. You should not take methylphenidate on the day of your surgery if a certain type of anaesthetic is used. This is because there is a chance of a sudden rise in blood pressure during the operation.</p><p><br /><strong>Drug testing</strong><br />This medicine may give a positive result when testing for drug use. This includes testing used in sport.</p><p><br /><strong>Concentia with alcohol</strong><br />Do not drink alcohol while taking this medicine. Alcohol may make the side effects of this medicine worse. Remember that some foods and medicines contain alcohol.</p><p><br /><strong>Pregnancy, breast-feeding and contraception</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.<br />. Available data do not suggest an increased risk of overall birth defects, whilst a small increase in the risk of malformations of the heart when used during the first three months of pregnancy could not be ruled out. Your doctor will be able to give you more information about this risk. Tell your doctor or pharmacist before using methylphenidate if you or your daughter:<br />&bull; having sex. Your doctor will discuss contraception with you<br />&bull; pregnant or think you may be pregnant. Your doctor will decide whether you should take methylphenidate.<br />&bull; breast-feeding or planning to breast-feed. Methylphenidate passes into breast milk. Therefore, your doctor will decide whether you should breast-feed while taking methylphenidate.</p><p><br /><strong>Driving and using machines</strong><br />You may feel dizzy, have problems focussing or have blurred vision when taking methylphenidate. If these happen it may be dangerous to do things such as drive, use machines, ride a bike or horse or climb trees.</p><p><br /><strong>Concentia contains lactose</strong><br />This medicine contains lactose (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take</strong><br />Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />&bull; your doctor will usually start treatment with a low dose and increase it gradually as required.<br />&bull; the maximum daily dose is 54 mg.<br />&bull; you should take Concentia once each day in the morning with a glass of water.<br />The tablet should be swallowed whole and not chewed, broken, or crushed. The tablet may be taken with or without food.<br />The tablet does not dissolve completely after all of the drug has been released and sometimes the tablet shell may appear in your stools. This is normal.</p><p><br /><strong>If you do not feel better after 1 month of treatment</strong><br />If you do not feel better, tell your doctor. They may decide you need a different treatment.</p><p><br /><strong>Not using Concentia properly</strong><br />If Concentia is not used properly, this may cause abnormal behaviour. It may also mean that you start to depend on the medicine. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines or street drugs.<br />This medicine is only for you. Do not give this medicine to anyone else, even if their symptoms seem similar.</p><p><br /><strong>If you take more Concentia than you should</strong><br />If you take too much medicine, talk to a doctor or call an ambulance straight away. Tell them how much has been taken.<br />Signs of overdose may include: being sick, feeling agitated, shaking, increased uncontrolled movements, muscle twitching, fits (may be followed by coma), feeling very happy, being confused, seeing, feeling or hearing things that are not real (hallucinations), sweating, flushing, headache, high fever, changes in heart beat (slow, fast or uneven), high blood pressure, dilated pupils and dry nose and mouth.</p><p><br /><strong>If you forget to take Concentia</strong><br />Do not take a double dose to make up for a forgotten dose. If you forget a dose, wait until it is time for the next dose.</p><p><br /><strong>If you stop taking Concentia</strong><br />If you suddenly stop taking this medicine, the ADHD symptoms may come back or unwanted effects such as depression may appear. Your doctor may want to gradually reduce the amount of medicine taken each day, before stopping it completely. Talk to your doctor before stopping Concentia.</p><p><br /><strong>Things your doctor will do when you are on treatment</strong><br />Your doctor will do some tests<br />&bull; before you start - to make sure that Concentia is safe and will be of benefit.<br />&bull; after you start - they will be done at least every 6 months, but possibly more often. They will also be done when the dose is changed.<br />&bull; these tests will include:<br />- checking your appetite<br />- measuring height and weight<br />- measuring blood pressure and heart rate<br />- checking whether you have any problems with your mood, state of mind or any other unusual feelings. Or if these have got worse while taking Concentia.<br />Long-term treatment<br />Concentia does not need to be taken for ever. If you take Concentia for more than a year, your doctor should stop treatment for a short time, this may happen during a school holiday. This will show if the medicine is still needed.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Although some people get side effects, most people find that methylphenidate helps them. Your doctor will talk to you about these side effects.</p><p><br /><strong>Some side effects could be serious. If you have any of the side effects below, see a doctor straight away:<br />Common (may affect up to 1 in 10 people)</strong><br />&bull; uneven heartbeat (palpitations)<br />&bull; mood changes or mood swings or changes in personality<br />&bull; excessive teeth grinding (bruxism)</p><p><br /><strong>Uncommon (may affect up to 1 in 100 people)</strong><br />&bull; thinking about or feeling like killing yourself<br />&bull; seeing, feeling, or hearing things that are not real, these are signs of psychosis<br />&bull; uncontrolled speech and body movements (Tourette&rsquo;s)<br />&bull; signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing</p><p><br /><strong>Rare (may affect up to 1 in 1,000 people)</strong><br />&bull; feeling unusually excited, over-active and un-inhibited (mania)</p><p><br /><strong>Very rare (may affect up to 1 in 10,000 people)</strong><br />&bull; heart attack<br />&bull; sudden death<br />&bull; suicidal attempt<br />&bull; fits (seizures, convulsions epilepsy)<br />&bull; skin peeling or purplish red patches<br />&bull; inflammation or blocked arteries in the brain<br />&bull; temporary paralysis or problems with movement and vision, difficulties in speech (these can be signs of problems with the blood vessels in your brain)<br />&bull; muscle spasms which you cannot control affecting your eyes, head, neck, body and nervous system<br />&bull; decrease in number of blood cells (red cells, white cells and platelets) which can make you more likely to get infections, and make you bleed and bruise more easily<br />&bull; a sudden increase in body temperature, very high blood pressure and severe convulsions<br />(&lsquo;Neuroleptic Malignant Syndrome&rsquo;). It is not certain that this side effect is caused by methylphenidate or other drugs that may be taken in combination with methylphenidate.</p><p><br /><strong>Not known (frequency cannot be estimated from the available data)</strong><br />&bull; unwanted thoughts that keep coming back<br />&bull; unexplained fainting, chest pain, shortness of breath (these can be signs of heart problems)<br />&bull; paralysis or problems with movement and vision, difficulties in speech (these can be signs of problems with the blood vessels in your brain)<br />&bull; prolonged erections, sometimes painful or an increased number of erections.<br />&bull; inability to control the excretion of urine (incontinence)<br />&bull; spasm of the jaw muscles that makes it difficult to open the mouth (trismus)<br />&bull; stuttering<br />If you have any of the side effects above, see a doctor straight away.</p><p><br /><strong>Other side effects include the following, if they get serious, please tell your doctor or pharmacist: </strong></p><p><strong>Very common (may affect more than 1 in 10 people)</strong><br />&bull; headache<br />&bull; feeling nervous<br />&bull; not being able to sleep.</p><p><br /><strong>Common (may affect up to 1 in 10 people)</strong><br />&bull; joint pain<br />&bull; blurred vision<br />&bull; tension headache<br />&bull; dry mouth, thirst<br />&bull; trouble falling asleep<br />&bull; high temperature (fever)<br />&bull; problems with sex drive<br />&bull; unusual hair loss or thinning<br />&bull; muscle tightness, muscle cramps<br />&bull; loss of appetite or decreased appetite<br />&bull; inability to develop or maintain an erection<br />&bull; itching, rash or raised red itchy rashes (hives)<br />&bull; feeling unusually sleepy or drowsy, feeling tired<br />&bull; clenching or grinding your teeth, feeling of panic<br />&bull; tingling feeling, prickling, or numbness of the skin<br />&bull; increased alanine aminotransferase (liver enzyme) level in your blood<br />&bull; cough, sore throat or nose and throat irritation; upper respiratory tract infection; sinus infection<br />&bull; high blood pressure, fast heart beat (tachycardia)<br />&bull; dizziness (vertigo), feeling weak, movements which you cannot control, being unusually active<br />&bull; feeling aggressive, agitated, anxious, depressed, irritable, tense, jittery and abnormal behaviour<br />&bull; upset stomach or indigestion, stomach pain, diarrhoea, feeling sick, stomach discomfort and being sick.<br />&bull; excessive sweating.</p><p><br /><strong>Uncommon (may affect up to 1 in 100 people)</strong><br />&bull; dry eyes<br />&bull; constipation<br />&bull; chest discomfort<br />&bull; blood in the urine<br />&bull; listlessness<br />&bull; shaking or trembling<br />&bull; increased need to pass urine<br />&bull; muscle pain, muscle twitching<br />&bull; shortness of breath or chest pain<br />&bull; feeling hot<br />&bull; increases in liver test results (seen in a blood test)<br />&bull; anger, feeling restless or tearful, talking too much, excessive awareness of surroundings, problems sleeping.</p><p><br /><strong>Rare (may affect up to 1 in 1,000 people)</strong><br />&bull; feeling disorientated or confused<br />&bull; trouble seeing or double vision<br />&bull; swelling of the breasts in men<br />&bull; redness of the skin, red raised skin rash.</p><p><br /><strong>Very rare (may affect up to 1 in 10,000 people)</strong><br />&bull; muscle cramps<br />&bull; small red marks on the skin<br />&bull; abnormal liver function including sudden liver failure and coma<br />&bull; changes in test results &ndash; including liver and blood tests<br />&bull; abnormal thinking, lack of feeling or emotion, doing things over and over again, being obsessed with one thing<br />&bull; fingers and toes feeling numb, tingling and changing colour (from white to blue, then red) when cold (&lsquo;Raynaud&rsquo;s phenomenon&rsquo;).</p><p><br /><strong>Not known (frequency cannot be estimated from the available data)</strong><br />&bull; migraine<br />&bull; dilated pupils<br />&bull; very high fever<br />&bull; slow, fast or extra heart beats<br />&bull; a major fit (&lsquo;grand mal convulsions&rsquo;)<br />&bull; believing things that are not true<br />&bull; severe stomach pain, often with feeling and being sick</p><p><br /><strong>Effects on growth</strong><br />When used for more than a year, methylphenidate may cause reduced growth in some children. This affects less than 1 in 10 children.<br />&bull; there may be lack of weight gain or height growth.<br />&bull; your doctor will carefully watch your height and weight, as well as how well you are eating.<br />&bull; if you are not growing as expected, then your treatment with methylphenidate may be stopped for a short time.</p><p style="text-indent:50px"><br /><strong>Reporting of side effects<br />Saudi Arabia:</strong><br />The National Pharmacovigilance Centre (NPC).<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</p><p style="text-indent:50px"><br /><strong>United Arab Emirates:</strong><br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853 Tel: 80011111<br />Email : pv@mohap.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention, Dubai, UAE</p><p style="text-indent:50px"><br /><strong>Other GCC and Levant countries:</strong><br />Please contact your doctor or pharmacist or nurse to report any side effect. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&ordm;C.<br />Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.<br />Keep the bottle tightly closed in order to protect from moisture. The pack contains two small desiccant canisters. These pouches are used to keep the tablets dry and should not be eaten.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is methylphenidate hydrochloride<br />&bull; Concentia 18mg Prolonged Release Tablets contain 18mg of methylphenidate hydrochloride.<br />&bull; Concentia 36mg Prolonged Release Tablets contain 36mg of methylphenidate hydrochloride.<br />&bull; Concentia 54mg Prolonged Release Tablets contain 54mg of methylphenidate hydrochloride.<br />The other ingredients are:<br />&bull; Hypromellose, Polyethylene Oxide, Succinic Acid, Magnesium Stearate, Sodium Chloride, Colloidal silicon dioxide, Black Iron Oxide.<br />&bull; Film coating: Cellullose Acetate, Polyethylene Glycol.<br />&bull; Clear coating: Hypromellose, Polyethylene glycol/ Macrogol, Phosphoric Acid.<br />&bull; Color coating: Lactose Monohydrate, Hypromellose, Titanium dioxide, Triacetin, Yellow Iron Oxide, Red Iron Oxide, Lactose Monohydrate, Ferrosoferric Oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Concentia is available in four strengths: 18 mg, 27 mg, 36 mg and 54 mg. Each tablet is a different colour to aid identification:
• 18 mg: Round, biconvex, yellow film-coated tablets of approximately 9 mm of diameter with a small hole in one side of the tablet.
• 27 mg: Round, biconvex, grey film-coated tablets of approximately 9 mm of diameter with a small hole in one side of the tablet.
• 36 mg: Round, biconvex, white film-coated tablets of approximately 10 mm of diameter with a small hole in one side of the tablet.
• 54 mg: Round, biconvex, pink film-coated tablets of approximately 10 mm of diameter with a small hole in one side of the tablet
The medicinal product is available in bottles containing 30 prolonged release tablet; 60 prolonged release tablet (2x30) and 90 prolonged release tablet (3x30). Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Exeltis Healthcare S.L.<br />Pol. Ind. Miralcampo. Avda. Miralcampo, 7.<br />19200 Azuqueca de Henares. Guadalajara<br />Spain<br /><strong>Manufacturer:</strong><br />Laboratorios Liconsa S.A.,<br />Avda. Miralcampo, N&ordm;7, PI Miralcampo,<br />19200- Azuqueca de Henares - Guadalajara, Spain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يٌستخدم <strong>كونسنتيا&nbsp;</strong>لعلاج &quot; اضطراب نقص الانتباه مع فرط النشاط &quot; ( ADHD )</p><p>&bull; لدى الأطفال والشباب الذين تتراوح أعمارهم بين 6 و 18 عاماً</p><p>&bull;فقط بعد تجربة العلاجات التي لا تحتوي على أدوية . مثل الاستشارة والعلاج السلوكي.&nbsp;</p><p>لا&nbsp;يٌستخدم <strong>كونسنتيا&nbsp;</strong>&nbsp;معلاج لاضطراب نقص الانتباه&nbsp;مع فرط النشاط لدى الاطفال&nbsp;( ADHD ) دون سن 6 سنوات أو لبدء العلاج عند البالغين. عند بدأ العلاج في سن أصغر ، قد يكون من المناسب الاستمرار في تناول دواء&nbsp;<strong>كونسنتيا&nbsp;</strong>&nbsp;عندما تصبح بالغاً. وسيقدم طبيبك المشورة لك بهذا الشأن.&nbsp;</p><p>&nbsp;</p><p><strong>كيف&nbsp;يعمل&nbsp;</strong></p><p>يحسن دواء&nbsp;<strong>كونسنتيا&nbsp;</strong>&nbsp;نشاط أجزاء معينة من الدماغ التي تعاني من نقص النشاط. يمكن أن يساعد الدواء في تحسين الانتباه ( مدى الانتباه) والتركيز وتقليل السلوك الاندفاعي. ويعطى الدواء كجزء من برنامج علاجي، والذي يضمن عادةً:&nbsp;</p><ul><li>الجانب النفسي</li><li>الجانب التعليمي و&nbsp;</li><li>العلاج الاجتماعي&nbsp;</li></ul><p>يتم وصف الدواء فقط من قبل الاطباء الذين لديهم خبرة في علاج مشاكل سلوك الاطفال أو الشباب. على الرغم من عدم وجود علاج لاضطراب نقص الانتباه مع فرط النشاط، الا أنه يمكن إدارته باستخدام برنامج العلاج.&nbsp;</p><p><strong>عن اضطراب نقص الانتباه مع فرط النشاط ADHD</strong></p><p>&nbsp;يعاني الأطفال والشباب المصابون باضطراب نقص الانتباه مع فرط النشاط ADHD من :&nbsp;</p><ul><li dir="rtl">صعوبة في الجلوس بهدوء&nbsp;</li><li dir="rtl">صعوبة في التركيز</li></ul><p>ولا يمكن إلقاء اللوم عليهم إن كان ليس بوسعهم القيام بهذه الأشياء.&nbsp;</p><p>يكافح العديد من الأطفال و الشباب للقيام بهذه الاشياء . ومع ذلك ، يمكن أن يتسبب اضطراب نقص الانتباه مع فرط النشاط لدى الأطفال والشباب المصابون مشاكل في الحياة اليومية. وقد يواجه الأطفال والشباب المصابون باضطراب نقص الإنتباه مع فرط النشاط صعوبة في التعليم وأداء الواجبات المنزلية. كما يعانون من صعوبة في التصريف بشكل جيد في المنزل أو في المدرسة أو في أماكن أخرى. كما لا يؤثر اضطراب نقص الانتباه مع فرط النشاط على ذكاء الطفل أو الشاب.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تجنب تناول دواء&nbsp;<strong>كونسنتيا&nbsp;</strong>&nbsp;في حال:&nbsp;</p><ul><li dir="rtl">كان لديك حساسية من مثايلفنديت أو أي من المكونات الاخرى لهذا الدواء ( المدرجة في القسم 6 )&nbsp;</li><li dir="rtl">كان لديك مشاكل في الغدة الدرقية&nbsp;</li><li dir="rtl">كان لديك زيادة في الضغط في عينك (المياة الزرقاء)</li><li dir="rtl">كان لديك ورم في الغدة الكظرية&nbsp;(ورم القواتم).</li><li dir="rtl">لديك مشكلة في الأكل عندما لا تشعر بالجوع أو ترغب في تناول الطعام ، مثل &quot; فقد الشهية العصبي &quot;&nbsp;</li><li dir="rtl">كنت تعاني من ارتفاع شديد في ضغط الدم أو تضيق في الأوعية الدموية، مما يتسبب في ألم في الذراعين والساقين.&nbsp;</li><li dir="rtl">كان لديك مشاكل في القلب - مثل النوبة القلبية أو عدم انتظام ضربات القلب أو الألم وعدم الراحة في الصدر أو فشل القلب أو أمراض القلب أو في حال ولدت بمشكلة في القلب.</li><li dir="rtl">كنت تعاني من مشكلة في الأوعية الدموية في دماغك، مثل السكتة الدماغية أو التورم وضعف جزء من الأوعية الدموية ( تمدد الأوعية الدموية) أو الأوعية الدموية الضيقة أو المسدودة أو التهاب الأوعية الدموية (الالتهاب الوعائي)&nbsp;</li><li dir="rtl">كنت تتناول في الوقت الحالي أو تناولت خلال آخر 14 يوما مضادا للاكتئاب ( يعرف باسم مثبطات الأوكسيداز أحادي الأمين) - انظر &quot; الأدوية الأخرى و كونسنتيا&quot;&nbsp;</li><li dir="rtl">كنت تعاني من مشاكل نفسية مثل:&nbsp;</li></ul><p>- مشكلة &quot; مختل عقلياُ &quot; أو &quot; انفصام الحدية&quot;&nbsp;</p><p>- أفكار أو رؤى غير طبيعية أو مرض يسمى &quot;انفصام الشخصية&quot;</p><p>-علامات مشكلة مزاجية حادة مثل:&nbsp;</p><ul><li dir="rtl">الشعور وكأنك&nbsp;تقتل نفسك</li><li dir="rtl">الاكتئاب الحاد.&nbsp;حيث تشعر بالحزن الشديد&nbsp;وبفقدان القيمة واليأس.&nbsp;</li><li dir="rtl">الهوس،&nbsp;حيث تشعر&nbsp;بالإثارة بشكل غير عادي والنشاط المفرط والجرأة.</li><li dir="rtl">لا تتناول&nbsp;مِثايلفنِديت في حال كان&nbsp;ينطبق عليك أياً مما سبق. وإذا&nbsp;لم تكن متأكداً ،&nbsp;تحدث إلى&nbsp;طبيبك أو الصيدلي&nbsp;قبل تناول&nbsp;مِثايلفنِديت&nbsp;وذلك لأن&nbsp;تناول&nbsp;مِثايلفنِديت&nbsp;يمكن أن يجعل&nbsp;هذه&nbsp;المشاكل&nbsp;أسوأ.&nbsp;</li></ul><p><strong>التحذيرات والاحتياطات</strong></p><p>تحدث إلى&nbsp;طبيبك&nbsp;قبل تناول دواء&nbsp;كونسنتيا&nbsp;إذا:</p><ul><li dir="rtl">كان لديك مشاكل&nbsp;في الكبد أو الكلى.&nbsp;</li><li dir="rtl">كان لديك مشكلة في البلع أو بلع أقراص كاملة.</li><li dir="rtl">كان لديك تضيق أو انسداد&nbsp;في&nbsp;أمعائك أو أنبوب&nbsp;الطعام.&nbsp;</li><li dir="rtl">كنت تعاني&nbsp;من نوبات&nbsp;(الاختلاجات، التشنجات، الصرع) أو أي صور غير&nbsp;&nbsp;اعتيادية&nbsp;للدماغ (التخطيط&nbsp;الكهربائي&nbsp;للدماغ).</li><li dir="rtl">كان قد سبق لك أن تعاطيت أو&nbsp;أدمنت على&nbsp;الكحول&nbsp;أو الأدوية&nbsp;الموصوفة&nbsp;أو المخدرات&nbsp;&nbsp;الغير&nbsp;مشروعة.&nbsp;</li><li dir="rtl">كنتِ فتاة و بدأت&nbsp;دورتكِ&nbsp;الشهرية&nbsp;(انظر القسم&nbsp;أدناه &quot; الحمل&nbsp;والرضاعة&nbsp;ومنع الحمل&quot;).</li><li dir="rtl">كان لديك ارتعاش&nbsp;متكرر&nbsp;لا يمكن السيطرة&nbsp;عليه في أي جزء من الجسم&nbsp;أو كنت&nbsp;تكرر&nbsp;الأصوات&nbsp;والكلمات.&nbsp;</li><li dir="rtl">كنت تعاني&nbsp;من ارتفاع في ضغط الدم&nbsp;</li><li dir="rtl">كان لديك مشكلة في القلب ليست غير&nbsp;مذكورة في قسم&quot;لا تتناول&quot; أعلاه.&nbsp;</li><li dir="rtl">كان لديك مشكلة نفسيه غير&nbsp;مذكورة&nbsp;في قسم&quot;لا تتناول&quot; أعلاه.</li></ul><p>تتضمن&nbsp;المشاكل&nbsp;النفسية&nbsp;الأخرى&nbsp;ما يلي:&nbsp;</p><p>-&nbsp;تقلبات المزاج&nbsp;(من الهوس إلى الاكتئاب - يسمى &quot;&nbsp;الاضطراب&nbsp;ثنائي القطب&quot; )</p><p>-الشعور بالعدوانية&nbsp;أو العدائية</p><p>-رؤية&nbsp;أو سماع&nbsp;أشياء غير&nbsp;موجودة أو الشعور بها (الهلوسة).</p><p>-&nbsp;تصديق أشياء غير صحيحة (أوهام).</p><p>-الشعور بالشك&nbsp;والريبة بشكل غير&nbsp;معتاد&nbsp;(البارانويا)&nbsp;- الشعور بالهياج&nbsp;أو القلق أو التوتر -&nbsp;الشعور بالاكتئاب أو الذنب.</p><p>في حال كان ينطبق عليك أياً مما سبق، أخبر طبيبك أو الصيدلي&nbsp;قبل بدء العلاج.&nbsp;وذلك لأن تناول&nbsp;مثيلفِنيدات يمكن أن يجعل هذه المشاكل&nbsp;أسوأ.&nbsp;سيحرص طبيبك على مراقبة&nbsp;مدى تأثير&nbsp;الدواء عليك.&nbsp;</p><p>خلال العلاج،&nbsp;قد يعاني الأولاد والمراهقون بشكل غير توقع من انتصاب القضيب لفترة طويلة. قد يكون&nbsp;هذا مؤلماً ويمكن أن يحدث في أي وقت. ومن الضروري أن تتصل بطبيبك على الفور&nbsp;إذا استمر انتصاب&nbsp;القضيب لمدة تزيد&nbsp;عن ساعتين،&nbsp;خاصة إذا كان هذا مؤلماً.</p><p><strong>الفحوصات التي سيجريها طبيبك قبل البدء في تناول دواء&nbsp;كونسنتيا&nbsp;</strong>&nbsp;</p><p>تهدف هذه الفحوصات إلى&nbsp;تحديد ما إذا كان&nbsp;مثيلفِنيدات هو الدواء المناسب لك. سيتحدث طبيبك معك عن:</p><ul><li dir="rtl">أي أدوية اخرى تتناولها.&nbsp;</li><li dir="rtl">ما إذا كان هناك أي سجل عائلي&nbsp;للموت المفاجئ غير المفسر.&nbsp;</li><li dir="rtl">أي مشاكل طبيبة أخرى (&nbsp;مثل مشاكل القلب) قد تعاني منها أنت أو عائلتك.&nbsp;</li><li dir="rtl">شعورك، مثل المزاج الجيد&nbsp;أو المزاج السيء ، أو&nbsp;وجود أفكار&nbsp;غريبة&nbsp;أو إذا كان لديك أي من هذه المشاعر في&nbsp;الماضي.&nbsp;</li><li dir="rtl">ما إذا كان هناك سجل عائلي&nbsp;من &quot; الحركات الاإرادية&quot; (لا يمكن السيطرة عليها، الارتعاش المتكرر&nbsp; في أي جزء من الجسم أو كنت تكرر الأصوات والكلمات).</li><li dir="rtl">أي مشاكل&nbsp;نفسية أو سلوكية&nbsp;عانيت منها&nbsp;أنت أو أفراد&nbsp;أسرتك. سيناقش&nbsp;طبيبك ما إذا كنت&nbsp;معرضاً لخطر الإصابة&nbsp;بتقلبات مزاجية&nbsp;(من الهوس إلى&nbsp;الاكتئاب - يسمى&nbsp;&quot;الاضطراب ثنائي القطب&quot;).&nbsp;و سيقوم بفحص سجلك النفسي.&nbsp;والتحقق مما إذا كان لدى أي من أفراد عائلتك سجل&nbsp;من الانتحار أو الاضطراب ثنائي القطب أو الاكتئاب.&nbsp;</li><li dir="rtl">من الضروري&nbsp;أن تقدم أكبر&nbsp;قدر ممكن من المعلومات،&nbsp;إذ سيساعد هذا&nbsp;طبيبك على&nbsp;تحديد ما إذا كان ثايلفنِديت هو&nbsp;الدواء المناسب لك. قد&nbsp;يقرر طبيبك أن هناك حاجة إلى&nbsp;فحوصات طبية&nbsp;أخرى قبل البدء في تناول هذا الدواء.&nbsp;</li></ul><p><strong>أدوية أخرى&nbsp;كونسنتيا&nbsp;&nbsp;&nbsp;</strong></p><p>أخبر&nbsp;طبيبك&nbsp;إذا كنت&nbsp;تتناول أو تناولت&nbsp;مؤخرًا أو قد&nbsp;تتناول أي أدوية&nbsp;أخرى.</p><p>لا تتناول مِثايلفنِديت إذا كنت:</p><ul><li dir="rtl">تتناول&nbsp;دواء يسمى&nbsp; &quot;مثبطات الأوكسيداز أحادي الأمين&quot;&nbsp;المستخدم لعلاج الاكتئاب،&nbsp;أو تناولت مثبطات الأوكسيداز&nbsp;أحادي&nbsp;الأمين في آخر&nbsp; 14 يوماً.&nbsp;قد يؤدي تناول مثبطات الأوكسيداز&nbsp;&nbsp;أحادي الأمين&nbsp;مع مِثايلفنِديت إلى زيادة&nbsp;مفاجئة في&nbsp;ضغط الدم&nbsp;لديك.</li></ul><p>أخبر&nbsp;طبيبك أو الصيدلي&nbsp;إذا كنت تتناول أنت أو طفلك أياً&nbsp;من أدوية&nbsp;الاكتئاب أو القلق التالية:</p><ul><li dir="rtl">مضادات الاكتئاب ثلاثية الحلقات&nbsp;</li><li dir="rtl">مثبطات استرداد السيروتونين الانتقائية</li><li dir="rtl">مثبطات استرداد السيروتونين&nbsp;والنورابينفرين</li></ul><p>يمكن أن يؤدي تناول مِثايلفنِديت مع هذه الأنواع من&nbsp;الأدوية إلى زيادة&nbsp;&quot;السيروتونين&quot; في&nbsp;الدماغ بشكل يهدد الحياة (متلازمة&nbsp;السيروتونين ) ،&nbsp;مما قد يؤدي إلى&nbsp;الشعور بالارتباك&nbsp;أو القلق أو&nbsp;التعرق أو&nbsp; الارتعاش أو&nbsp;تقلص العضلات أو ضربات&nbsp;القلب السريعة.&nbsp;</p><p>إذا أصبت أنت أو طفلك بهذه&nbsp;الآثار الجانبية،&nbsp;فاستشر الطبيب على&nbsp;الفور.</p><p>إذا كنت&nbsp;تتناول أدوية&nbsp;أخرى، قد يؤثر&nbsp;مِثايلفنِديت على&nbsp;آلية عملها أو قد يسبب&nbsp;آثارًا&nbsp;جانبية.استشر طبيبك أو الصيدلي&nbsp;قبل تناول&nbsp;مِثايلفنِديت، في حال كنت تتناول أيا من الأدوية التالية:&nbsp;</p><ul><li dir="rtl">أدوية المشاكل النفسية الشديدة</li><li dir="rtl">أدوية&nbsp;مرض&nbsp;باركنسون ( مثل&nbsp;ليفودوبا)&nbsp;</li><li dir="rtl">أدوية&nbsp;الصرع</li><li dir="rtl">الأدوية&nbsp;المستخدمة لخفض&nbsp;أو زيادة ضغط الدم.</li><li dir="rtl">بعض علاجات السعال والزكام التي تحتوي على أدوية&nbsp;يمكن أن تؤثر على&nbsp;ضغط الدم. من&nbsp;الضروري مراجعة الصيدلي&nbsp;عند شراء أي من هذه المنتجات.</li><li dir="rtl">الأدوية التي&nbsp;تضعف الدم لمنع تجلط الدم.&nbsp;</li></ul><p>اذا كان&nbsp;لديك أي شك فيما&nbsp;إذا كانت&nbsp;أي أدوية&nbsp;تتناولها&nbsp;مدرجة في القائمة أعلاه، اسأل طبيبك أو الصيدلي&nbsp;قبل تناول&nbsp;مِثايلفنِديت.</p><p>يرجى إخبار الطبيب أو الصيدلي&nbsp;إذا كنت تتناول&nbsp;أو تناولت مؤخرًا أي&nbsp;أدوية&nbsp; أخرى،&nbsp;بما في ذلك&nbsp;الأدوية التي&nbsp;تم الحصول عليها بدون وصفة طبية.&nbsp;</p><p><strong>العملية الجراحية</strong></p><p>أخبر طبيبك إذا كنت ستخضع لعملية جراحية. يجب ألا تتناول مِثايلفنِديت&nbsp;في&nbsp;يوم الجراحة&nbsp;إذا تم استخدام نوع معين من التخدير،&nbsp;فمن المحتمل&nbsp;حدوث ارتفاع مفاجئ في ضغط الدم أثناء العملية.</p><p><strong>اختبار المخدرات</strong></p><p>قد يعطي هذا الدواء نتيجة إيجابية عند اختبار تعاطي&nbsp;المخدرات.&nbsp;وهذا يشمل الاختبارات المستخدمة في الرياضة.</p><p><strong>كونسنتيا مع الكحول&nbsp;</strong></p><p>لا تشرب الكحول أثناء تناول هذا الدواء. قد يجعل الكحول الآثار الجنابية لهذا الدواء أسوأ.&nbsp;تذكر أن بعض&nbsp;الأطعمة&nbsp;والأدوية&nbsp;تحتوي&nbsp;على الكحول.&nbsp;</p><p><strong>الحمل والرضاعة ومنع الحمل&nbsp;</strong></p><p>إذا كنتِ حاملاً أو مرضعة أو تعتقدين بأنك حامل أو تخططين&nbsp;لإنجاب طفل، اسألي&nbsp;طبيبك للحصول على المشورة&nbsp;قبل تناول هذا الدواء&nbsp;</p><p>لا تشير&nbsp;البيانات المتاحة إلى زيادة خطر الإصابة بعيوب&nbsp;خلقية عامة،&nbsp;بينما لا يمكن&nbsp;استبعاد زيادة طفيفة في خطر حدوث تشوهات في&nbsp;القلب عند استخدامها خلال الأشهر الثلاثة الأولى من الحمل. سيتمكن طبيبك من تقديم المز يد&nbsp;من المعلومات حول هذا الخطر.&nbsp;</p><p>أخبري طبيبكِ أو الصيدلي،&nbsp;قبل استخدام مِثايلفنِديت إذا كنتِ أنت أو ابنتك:</p><ul><li dir="rtl">تمارسين الجنس.&nbsp;سيناقشك طبيبك&nbsp;حول وسائل منع الحمل&nbsp;</li><li dir="rtl">حامل أو تعتقدين&nbsp;بأنك حامل،&nbsp;سيقرر طبيبك ما إذا كان يجب عليك تناول مِثايلفنِديت.</li><li dir="rtl">مرضعة أو تخططين&nbsp;للرضاعة. ينتقل مِثايلفنِديت إلى&nbsp;حليب الثدي. لذلك، سيقرر&nbsp;طبيبك ما إذا كان يجب عليك الرضاعة&nbsp;&nbsp;أثناء تناول مِثايلفنِديت.</li></ul><p><strong>القيادة واستخدام الآليات</strong></p><p>عند تناول مِثايلفنِديت، قد تشعر&nbsp;بالدوار أو لديك مشاكل في التركيز أو تشوش الرؤية.&nbsp;إذا حدث ذلك، قد يكون من الخطر&nbsp;القيام&nbsp;بأشياء مثل القيادة أو استخدام&nbsp;الآليات أو ركوب&nbsp;الدراجة أو&nbsp;ركوب&nbsp; الخيل أو تسلق الأشجار.</p><p><strong>كونسنتيا يحتوي على&nbsp;اللاكتوز</strong></p><p>يحتوي هذا الدواء&nbsp;على&nbsp;اللاكتوز&nbsp;(نوع من السكر).&nbsp;إذا أخبرك&nbsp;طبيبك بأنك لا تسطيع تحمل بعض السكريات&nbsp;أو هضمها، تحدث إلى&nbsp;طبيبك قبل تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li><strong>الجرعة الموصى بها&nbsp;</strong></li></ul><p>احرص دائماً على&nbsp;تناول هذا الدواء تماماً كما أخبرك&nbsp;طبيبك تماماً . استشر&nbsp;طبيبك أو الصيدلي&nbsp;إذا لم تكن متأكداً .</p><ul><li dir="rtl">سيبدأ طبيبك العلاج عادةً&nbsp;بجرعة منخفضة ويزيدها&nbsp;تدريجيا&nbsp;حسب الحاجة.</li><li dir="rtl">الجرعة&nbsp;اليومية القصوى 54 مجم.&nbsp;</li><li dir="rtl">يجب أن تتناول&nbsp;كونسنتيا&nbsp;مرة واحدة في الصباح يومياً مع كوب من الماء.</li></ul><p>يجب ابتلاع القرص كاملاً وعدم مضغة أو تكسيره أو سحقه. يمكن تناول&nbsp;القرص مع الطعام أو بدونه.</p><p>بعد تحرر الدواء بالكامل&nbsp;داخل جسمك قد لا ينحل القرص&nbsp;تماماً. وربما تظهر قشرة القرص في&nbsp;برازك أحياناً . هذا امر طبيعي.&nbsp;</p><p><strong>إذا لم تشعر بتحسن بعد شهر من العلاج</strong></p><p>أخبر طبيبك،&nbsp;إن لم تشعر&nbsp;بتحسن، قد&nbsp;يقرر لك علاجاً مختلفاً.&nbsp;</p><p><strong>لا تستخدم&nbsp;كونسنتيا بشكل صحيح&nbsp;</strong></p><p>إذا لم يتم استخدام&nbsp;كونسنتيا&nbsp;بشكل صحيح، قد يتسبب ذلك في سلوك غير طبيعي. قد يعني أيضا أنك بدأت في&nbsp;الاعتماد على الدواء.&nbsp;</p><p>أخبر طبيبك&nbsp;إذا كان قد سبق لك أن تعاطيت أو أدمنت على&nbsp;الكحول أو الأدوية&nbsp;الموصوفة أو المخدرات الغير مشروعة.&nbsp;</p><p>هذا الدواء مخصص لك فقط.&nbsp;تجنب إعطاء هذا الدواء لأي شخص آخر ، حتى لو كانت الأعراض متشابهة.</p><p><strong>حال تناولت جرعة زائدة من&nbsp;كونسنتيا </strong></p><p>إذا تناولت الكثير&nbsp; من الادوية، تحدث الى الطبيب&nbsp;أو اتصل بالإسعاف على الفور. أخبرهم&nbsp;بالكمية التي تناولتها.&nbsp;</p><p>قد تشمل علامات الجرعة&nbsp;الزائدة:&nbsp;المرض&nbsp;والشعور بالاضطراب والارتجاف&nbsp; وزيادة الحركات الخارجة&nbsp;عن السيطرة وارتعاش&nbsp;العضلات و النوبات&nbsp;(قد تتبعها غيبوبة)&nbsp;</p><p>والشعور بالسعادة ا لمفرطة والارتباك ورؤية أو&nbsp;سماع أشياء غير حقيقة أو الشعور بها&nbsp;(الهلوسة) والتعرق والاحمرار&nbsp;والصداع و ارتفاع في درجة الحرارة وتغيرات في ضربات القلب (&nbsp;بطيئة أو سريعة أوغير منتظمة)&nbsp;و ارتفاع&nbsp;ضغط الدم و اتساع حدقة العين وجفاف&nbsp;الأنف والفم.</p><p><strong>في حال نسيان تناول&nbsp;كونسنتيا</strong></p><p>لا تتناول جرعة&nbsp;زائدة لتعويض الجرعة&nbsp;المنسية.&nbsp;وفي حال نسيت&nbsp;تناول&nbsp;الجرعة،&nbsp;انتظر حتى يحين&nbsp;موعد&nbsp;الجرعة التالية.&nbsp;</p><p><strong>في حال إيقاف تناول&nbsp;كونسنتيا</strong></p><p>في حال إيقاف تناول هذا الدواء بشكل مفاجئ، قد يعود أعراض اضطراب نقص الانتباه مع فرط النشاط أو قد تظهر آثار غير&nbsp;مرغوب مثل&nbsp;الاكتئاب.قبل إيقاف تناول الدواء بشكل نهائي،&nbsp;قد يرغب طبيبك في تقليل كمية الدواء التي&nbsp;يتم&nbsp;تناولها يومياً بشكل تدريجي.&nbsp;تحدث الى طبيبك&nbsp;قبل&nbsp;التوقف عن&nbsp;كونسنتيا.</p><p><strong>ما سيقوم به طبيبك أثناء فترة&nbsp;العلاج</strong></p><p><strong>سيقوم طبيبك&nbsp;بإجراء بعض الاختبارات&nbsp;</strong></p><ul><li dir="rtl">قبل أن تبدأ -&nbsp;تأكد من أن&nbsp;كونسنتيا&nbsp;آمن وذي فائدة.</li><li dir="rtl">بعد أن تبدأ - سيتم إجراء الاختبارات كل 6&nbsp;أشهر على الاقل،&nbsp;وربما&nbsp;أكثر.&nbsp;سيتم إجراء الاختبارات أيضاً عند تغيير الجرعة.</li><li dir="rtl">ستتضمن هذه الاختبارات:</li></ul><p>-&nbsp;التحقق من شهيتك</p><p>-قياس الطول والوزن</p><p>-قياس ضغط الدم ومعدل ضربات القلب.&nbsp;</p><p>-التحقق فيما إذا كان لديك أي مشاكل في مزاجك أو حالتك الذهنية أو أي مشاعر أخرى غير اعتديادية، أو في حال ساءت&nbsp;هذه الأعراض أثناء&nbsp;تناول&nbsp;كونسنتيا.</p><p><strong>علاج طويل الأمد</strong></p><p>لا تحتاج تناول&nbsp;كونسنتيا&nbsp;طوال حياتك. إذا كنت&nbsp;تتناول كونسنتيا&nbsp;لأكثر من&nbsp;عام،&nbsp;يجب أن يتوقف طبيبك عن العلاج لفترة قصيرة،&nbsp;وقد يحدث هذا خلال العطلة&nbsp; المدرسية. وبذلك&nbsp;ستتحقق فيما لو كنت&nbsp;لا تزال بحاجة للدواء.</p><p>اذا كان&nbsp;لديك مزيد&nbsp;من الأسئلة&nbsp;حول استخدام هذا المنتج،&nbsp;اسأل طبيبك أو الصيدلي.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الأدوية،&nbsp;يمكن أن يسبب هذا الدواء آثارًا جانبية قد لا تظهر لدى الجميع. على الرغم&nbsp;من أن بعض الأشخاص يعانون من&nbsp;آثار جانبية،&nbsp;إلا أن معظم الناس&nbsp;يجدون أن مِثايلفنِديت يساعدهم في التحسن. سيتحدث طبيبك معك عن هذه الآثارا&nbsp; الجانبية.</p><p><strong>قد تكون بعض&nbsp;الآثار الجانبية خطيرة&nbsp;إذا كان لديك&nbsp;أياً من الآثار الجانبية&nbsp;أدناه، استشر الطبيب على الفور:&nbsp;</strong></p><p><strong>الآثار&nbsp;الجانبية&nbsp;&nbsp;الشائعة&nbsp;(قد تظهر لدى شخص واحد من أصل 10 أشخاص)</strong></p><ul><li dir="rtl">عدم انتظام ضربات القلب&nbsp;(خفقان القلب)</li><li dir="rtl">تغيرات&nbsp;المزاج&nbsp;أو تقلبات المزاج أو&nbsp;تغيرات في الشخصية.&nbsp;</li><li dir="rtl">صرير تطاحن&nbsp;الأسنان المفرط (صرير&nbsp;الأسنان)</li></ul><p><strong>الآثار&nbsp;الجانبية غير الشائعة&nbsp;(قد تظهر لدى شخص واحد من أصل 100 أشخاص)</strong></p><ul><li dir="rtl">التفكير&nbsp;أو الشعور بالرغبة في قتل نفسك.&nbsp;</li><li dir="rtl">رؤية&nbsp;أو سماع أشياء غير&nbsp;حقيقية أو الشعور بها فهذه علامات على&nbsp;الذهان.</li><li dir="rtl">الكلام غير&nbsp;المنضبط وحركات الجسم&nbsp;(متلازمة&nbsp;توريت).</li><li dir="rtl">علامات الحساسية&nbsp;مثل الطفح الجلدي أو الحكة&nbsp;أو الشرى على الجلد&nbsp;أو تورم الوجة أو&nbsp;الشفتين&nbsp;أو اللسان أو أجزاء أخرى من الجسم أو ضيق التنفس أو صفير&nbsp;الصدر أو صعوبة التنفس.</li></ul><p><strong>لآثار&nbsp;الجانبية النادرة الحدوث&nbsp;(قد تظهر لدى شخص واحد من أصل 1000 أشخاص)</strong></p><ul><li>الشعور بالإثارة بشكل غير عادي&nbsp;والنشاط&nbsp;المفرط والجرأة (الهوس)</li></ul><p><strong>لآثار&nbsp;الجانبية النادرة جدا (قد تظهر لدى شخص واحد من أصل 10000 أشخاص)</strong></p><ul><li>ضربات&nbsp;القلب</li><li>الموت المفاجئ</li><li>محاولة الانتحار</li><li>نوبات&nbsp;(الاختلاجات ، التشنجات، الصرع)</li><li>تقشير الجلد أو بقع حمراء أرجوانية</li><li>التهاب أو انسداد&nbsp;الشرايين في&nbsp;الدماغ</li><li>شلل مؤقت أو مشاكل في الحركة و الرؤية&nbsp;أو صعوبات في الكلام (يمكن أن تكون هذه&nbsp; علامات&nbsp; على وجود مشاكل في&nbsp;الأوعية&nbsp;الدموية في دماغك)</li><li>تشنجات عضلية لا يمكنك السيطرة عليها&nbsp;وتؤثر على عينيك ورأسك&nbsp;وعنقك وجسمك وجهازك العصبي.&nbsp;</li><li>انخفاض في عدد خلايا&nbsp;الدم (الخلايا الحمراء والخلايا البيضاء&nbsp;والصفائح&nbsp;الدموية )&nbsp;مما قد يجعلك أكثر عرضة للاصابة بالعدوى والنزيف وظهور كدمات بسهولة.&nbsp;&nbsp;</li><li>ارتفاع مفاجئ في&nbsp;درجة حرارة الجسم&nbsp;وارتفاع شديد في&nbsp;ضغط الدم و تشنجات شديدة (&quot;متلازمة الذهان الخبيث&quot;)&nbsp;ليس&nbsp;من المؤكد أن هذا التأثير الجانبي&nbsp;ناتج عن&nbsp;مِثايلفنِديت أو الادوية&nbsp;الأخرى التي يمكن تناولها معه.&nbsp;</li></ul><p>&nbsp;</p><p><strong>آثار جانبية غير معروفة&nbsp;(لا يمكن تقدير عدد&nbsp;تكرار الحالات&nbsp;من البيانات المتاحة)</strong></p><ul><li>الافكار غير المرغوب فيها التي تظهر باستمرار&nbsp;</li><li>إغماء غير مفسر ،&nbsp;ألم في الصدر،&nbsp;ضيق في التنفس&nbsp;(يمكن أن تكون&nbsp;هذه علامات لمشاكل في القلب)&nbsp;</li><li>شلل أو مشاكل في الحركة والرؤية أو صعوبات في الكلام (&nbsp;يمكن أن تكون&nbsp;هذه&nbsp;علامات على وجود مشاكل في الأوعية الدموية في دماغك)&nbsp;</li><li>انتصاب القضيب المؤلم أحياناً لفترة طويلة، أو زيادة عدد مرات الانتصاب.<p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التحكم في إفراز البول (سلس البول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج عضلات الفك حيث من الصعب فتح الفم (تشنج عضلات الفك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التلعثم</p></li></ul><p dir="RTL">إذا كان لديك أي من الآثار الجانبية المذكورة أعلاه، استشر الطبيب على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تشمل الآثار الجانبية الأخرى ما يلي، في حال أصبحت خطرة، يرجى إخبار طبيبك أو الصيدلي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أثار جانبية شائعة جداً (قد تؤثر على أكثر من شخص واحد من أصل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأثار الجانبية الشائعة (قد تظهر لدى شخص واحد من أصل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صداع التوتر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم والعطش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ارتفاع في درجة الحرارة (حمى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مشاكل الدافع الجنسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تساقط الشعر بشكل غير اعتيادي أو ترققه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق العضلات وتشنجات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان أو قلة الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على تطوير أو الحفاظ على الانتصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة أو طفح جلدي أو طفح جلدي أحمر بارز مصحوب بحكة (الشرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس أو الخمول بشكل غير اعتيادي أو الشعور بالتعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العض على الأسنان أو صرير أسنانك أو الشعور بالهلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بوخز أو الخدر أو تنميل في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم ناقلة أمين الألانين (إنزيم الكبد) في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال والتهاب الحلق أو تهيج الأنف والحنجرة؛ عدوى الجهاز التنفسي العلوي أو التهابات الجيوب الانفية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم وسرعة ضربات القلب (تسرع القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة (دوار) الشعور بالضعف، حركات لا يمكنك السيطرة عليها، نشاط غير اعتيادي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعدوانية والإثارة والقلق والاكتئاب وسرعة الانفعال والتوتر والعصبية والسلوك غير الطبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في المعدة أو عسر هضم وآلام في المعدة والإسهال والغثيان وشعور مزعج في المعدة والمرض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق المفرط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تظهر لدى شخص واحد من أصل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الراحة في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخمول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش أو الارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغبة متزايدة في التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وارتعاش العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس أو ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بارتفاع الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادات في نتائج اختبار الكبد (تُلاحظ في فحص الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغضب، الشعور بعدم الارتياح أو البكاء، التحدث كثيراً، الإدراك المفرط للمحيط، مشاكل النوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة الحدوث (</strong><strong>قد تظهر لدى شخص واحد من أصل 1000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم القدرة على الإدراك أو الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الرؤية أو الرؤية المزدوجة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الثدي عند الرجال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد، طفح جلدي مع احمرار متزايد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جداً </strong><strong>(</strong><strong>قد تظهر لدى شخص واحد من أصل 10,000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات حمراء صغيرة على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف الكبد غير الطبيعية بما في ذلك فشل الكبد المفاجئ والغيبوبة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في نتائج الاختبار - بما في ذلك اختبارات الكبد والدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفكير غير طبيعي، قلة الشعور أو العاطفة، القيام بالأشياء مراراً وتكراراً، الهوس بشيء واحد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالخدر في أصابع اليدين والقدمين والوخز وتغير اللون (من الأبيض إلى الأزرق ثم الأحمر) عند البرودة (&quot;ظاهرة رينود&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير معروفة (لا يمكن تقدير عدد تكرار الحالات من البيانات المتاحة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتساع حدقة العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى شديدة جداً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دقات قلب بطيئة أو سريعة أو زائدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة كبرى (&quot;التشنجات الكبرى&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاعتقاد بأشياء غير صحيحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة في المعدة، تترافق بالإحساس بالمرض</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات على النمو</strong></p><p dir="RTL">عند استخدامه لأكثر من عام، قد يتسبب مِثايلفنِديت في انخفاض النمو لدى بعض الأطفال. وهذه الأعراض قد تظهر لدى نسبة أقل من طفل واحد <strong>من أصل 10 أطفال.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون هناك نقص في زيادة الوزن أو الطول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيراقب طبيبك بحذر طولك ووزنك، بالإضافة إلى مستوى شهيتك للطعام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تنمو كما هو متوقع، قد يتوقف علاجك باستخدام مِثايلفنِديت لفترة قصيرة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">مركز الاتصال في الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإمارات العربية المتحدة:</strong></p><p dir="RTL">قسم التيقظ الدوائي والأجهزة الطبية</p><p dir="RTL">ص.ب: 1853، هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع، دبي، الإمارات العربية المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي ودول بلاد الشام الأخرى:</strong></p><p dir="RTL">يرجى الاتصال بطبيبك أو الصيدلي أو الممرضة للإبلاغ عن أي آثار جانبية. وهذا يتضمن أي آثار جانبية محتملة غير مذكورة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بدرجة حرارة دون 30 درجة مئوية.</p><p dir="RTL">احفظ هذا الدواء بعيداً عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">احتفظ بالزجاجة مغلقة بإحكام لحمايتها من الرطوبة. تحتوي العبوة على كيسين صغيرين لامتصاص الرطوبة. وتُستخدم هذه الأكياس للحفاظ على الأقراص جافة، وهي غير صالحة للأكل.</p><p>لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساهم هذه التدابير في حماية البيئة.</p><ul></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تُعتبر مِثايلفنِديت هيدروكلوريد المادة الفعالة لهذا الدواء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كونسنتيا 18 مجم أقراص ممتدة المفعول تحتوي على 18 مجم من مِثايلفنِديت هيدروكلوريد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كونسنتيا 36 مجم أقراص ممتدة المفعول تحتوي على 36 مجم من مِثايلفنِديت هيدروكلوريد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كونسنتيا 54 مجم أقراص ممتدة المفعول تحتوي على 54 مجم من مِثايلفنِديت هيدروكلوريد.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبروميلوز وأكسيد البولي إيثيلين وحمض السكسينيك وسترات المغنيسيوم وكلوريد الصوديوم وثاني أكسيد السيليكون الغروي وأكسيد الحديد الأسود.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلم مغلف: اسيتات السليلوزوبولي إيثيلين جلايكول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغليف شفاف: هيبروميلوز وبولي إيثيلين جلايكول/ ماكروغول، حمض الفوسفوريك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغليف ملون: لاكتوز مونوهيدرات وهيبروميلوز وثاني أكسيد التيتانيوم والترياسيتين وأكسيد الحديد الأصفر وأكسيد الحديد الأحمر واللاكتوز مونوهيدرات والأكسيد الحديدي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كونسنتيا متوفر بأربع درجات تركيز: 18 مجم، 27 مجم، 36 مجم و54 مجم. لكل قرص لون مختلف للمساعدة في التفريق بينهم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18 مجم: أقراص مستديرة صفراء اللون محدبة من الوجهين، مغلفة بفيلم، قطرها حوالي 9ملم مع ثقب صغير في جانب واحد من القرص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27 مجم: أقراص مستديرة رمادية اللون محدبة من الوجهين، مغلفة بفيلم، قطرها حوالي 9ملم مع ثقب صغير في جانب واحد من القرص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36 مجم: أقراص مستديرة بيضاء اللون محدبة من الوجهين، مغلفة بفيلم، قطرها حوالي 9ملم مع ثقب صغير في جانب واحد من القرص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 54 مجم: أقراص مستديرة وردية اللون محدبة من الوجهين، مغلفة بفيلم، قطرها حوالي 9ملم مع ثقب صغير في جانب واحد من القرص.</p><p dir="RTL">يتوفر المنتج الطبي في عبوات تحتوي على 30 قرص ممتدة المفعول و60 قرص ممتدة المفعول (2x30) و90 قرص ممتدة المفعول (3x30). قد لا يتم تسويق كافة أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">إكسيلتيس هيلث كير إس. إل.</p><p dir="RTL">بوليغونو إندستريال ميرالكامبو. أفدا ميرالكامبو، 7.</p><p dir="RTL">19200 أزوكويكا دي إيناريس. غوادالاخارا</p><p dir="RTL">اسبانيا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL"><strong>لابوراتوريز ليكونسا إس.إيه</strong></p><p dir="RTL">أفدا ميرالكامبو، إن 7، بي آي ميرالكامبو،</p><p>19200 أزوكويكا دي إيناريس. غوادالاخارا، اسبانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تعديل هذه النشرة لآخر مرة في يناير 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentia 18 mg; 27 mg; 36 mg; 54 mg prolonged release tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One prolonged-release tablet contains 18 mg; 27 mg; 36 mg; 54 mg of methylphenidate hydrochloride.
Excipients with known effect:
-	All strengths contain 6.49 mg of lactose
-	For the strenght of 18 and 27 mg, one prolonged release tablet contains 24 mg of sodium
-	For the strenght of 36 and 54 mg, one prolonged release tablet contains 48 mg of sodium For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release tablet.
18 mg

Round, biconvex, yellow film-coated tablets of approximately 9 mm of diameter with a hole in one side of the tablet.

27 mg

Round, biconvex, grey film-coated tablets of approximately 9 mm of diameter with a hole in one side of the tablet.

36 mg

Round, biconvex, white film-coated tablets of approximately 10 mm of diameter with a hole in one side of the tablet.

54 mg

Round, biconvex, pink film-coated tablets of approximately 10 mm of diameter with a hole in one side of the tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Attention-Deficit/Hyperactivity Disorder (ADHD)</u></p><p>Concentia is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to the current DSM criteria or ICD</p><p>&nbsp;</p><p>guidelines and should be based on a complete history and evaluation of the patient. Diagnosis cannot be made solely on the presence of one or more symptom.</p><p>The specific aetiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and specialised psychological, educational, and social resources.</p><p>A comprehensive treatment programme typically includes psychological, educational and social measures as well as pharmacotherapy and is aimed at stabilising children with a behavioural syndrome characterised by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired.</p><p>Concentia treatment is not indicated in all children with ADHD and the decision to use the drug must be based on a very thorough assessment of the severity and chronicity of the child&#39;s symptoms in relation to the child&#39;s age.</p><p>Appropriate educational placement is essential, and psychosocial intervention is generally necessary. Where remedial measures alone prove insufficient, the decision to prescribe a stimulant must be based on rigorous assessment of the severity of the child&#39;s symptoms. The use of methylphenidate should always be used in this way according to the licensed indication and according to prescribing/diagnostic guidelines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Treatment must be initiated under the supervision of a specialist in childhood and/or adolescent behavioural disorders.</p><p><strong>&nbsp;</strong></p><p><u>Pre-treatment screening</u></p><p>Prior to prescribing, it is necessary to conduct a baseline evaluation of a patient&#39;s cardiovascular status including blood pressure and heart rate. A comprehensive history should document concomitant medications, past and present co-morbid medical and psychiatric disorders or symptoms, family history of sudden cardiac/unexplained death and accurate recording of pre- treatment height and weight on a growth chart (see sections 4.3 and 4.4).</p><p><u>Ongoing monitoring</u></p><p>Growth, psychiatric and cardiovascular status should be continuously monitored (see also section 4.4).</p><p>&bull;&nbsp; Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months;</p><p>&bull;&nbsp; Height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart;</p><p>&bull;&nbsp; Development of <em>de novo </em>or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit.</p><p>Patients should be monitored for the risk of diversion, misuse and abuse of methylphenidate. <u>Posology</u></p><p><em>Dose titration</em></p><p>Careful dose titration is necessary at the start of treatment with Concentia. Dose titration should be started at the lowest possible dose. A 27 mg dosage strength is available for those who wish to prescribe between the 18 mg and 36 mg dosages.</p><p>Other strengths of this medicinal product and other methylphenidate-containing products may be available.</p><p>Dosage may be adjusted in 18 mg increments In general, dosage adjustment may proceed at approximately weekly intervals.</p><p>The maximum daily dosage of Concentia is 54 mg.</p><p>&nbsp;</p><p><em>Patients New to Methylphenidate: </em>Clinical experience with Concentia is limited in these patients (see section 5.1). Concentia may not be indicated in all children with ADHD syndrome. Lower doses of short-acting methylphenidate formulations may be considered sufficient to treat patients new to methylphenidate. Careful dose titration by the physician in charge is required in order to avoid unnecessarily high doses of methylphenidate. The recommended starting dose of</p><p>Concentia for patients who are not currently taking methylphenidate, or for patients who are on stimulants other than methylphenidate, is 18 mg once daily.</p><p><em>Patients Currently Using Methylphenidate: </em>The recommended dose of Concentia for patients who are currently taking methylphenidate three times daily at doses of 15 to 45 mg/day is provided in Table 1. Dosing recommendations are based on current dose regimen and clinical judgement.</p><p>&nbsp;</p><p>TABLE 1</p><p><strong>Recommended Dose Conversion from Other Methylphenidate Hydrochloride Regimens, where available, to Concentia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Previous Methylphenidate Hydrochloride Daily Dose</strong></p></td><td style="vertical-align:top"><p><strong>Recommended Concentia Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>5 mg Methylphenidate three times daily</p></td><td style="vertical-align:top"><p>18 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>10 mg Methylphenidate three times daily</p></td><td style="vertical-align:top"><p>36 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>15 mg Methylphenidate three times daily</p></td><td style="vertical-align:top"><p>54 mg once daily</p></td></tr></tbody></table><p>&nbsp;</p><p>If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.</p><p><em>Long-term (more than 12 months) use in children and adolescents</em></p><p>The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. Methylphenidate treatment is usually discontinued during or after puberty. The physician who elects to use methylphenidate for extended periods (over 12 months) in children and adolescents with ADHD should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient&#39;s functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the child&#39;s condition (preferable during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued.</p><p><em>Dose reduction and discontinuation</em></p><p>Treatment must be stopped if the symptoms do not improve after appropriate dosage adjustment over a one-month period. If paradoxical aggravation of symptoms or other serious adverse events occur, the dosage should be reduced or discontinued.</p><p><em>Adults</em></p><p>In adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment, it may be appropriate to continue treatment into adulthood. However, start of treatment with Concentia in adults is not appropriate (see sections 4.4 and 5.1).</p><p><em>Elderly</em></p><p>Methylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group.</p><p><em>Children under 6 years of age</em></p><p>Methylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.</p><p><u>Method of administration</u></p><p>Concentia must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed (see section 4.4).</p><p>Concentia may be administered with or without food (see section 5.2).</p><p>&nbsp;</p><p>Concentia is taken once daily in the morning.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to methylphenidate or to any of the excipients listed in section 6.1
•	Glaucoma
•	Phaeochromocytoma
•	During treatment with non-selective, irreversible monoamine oxidase (MAO) inhibitors, or within a minimum of 14 days of discontinuing those drugs, due to the risk of hypertensive crisis (see section 4.5)
•	Hyperthyroidism or Thyrotoxicosis
•	Diagnosis or history of severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder
•	Diagnosis or history of severe and episodic (Type I) Bipolar (affective) Disorder (that is not well- controlled)
•	Pre-existing cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels)
•	Pre-existing cerebrovascular disorders cerebral aneurysm, vascular abnormalities including vasculitis or stroke


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methylphenidate treatment is not indicated in all children with ADHD and the decision to use the drug must be based on a very thorough assessment of the severity and chronicity of the child&#39;s symptoms in relation to the child&#39;s age.</p><p><u>Long-term use (more than 12 months) in children and adolescents</u></p><p>The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. Methylphenidate treatment is usually discontinued during or after puberty. Patients on long-term therapy (i.e. over 12 months) must have careful ongoing monitoring according to the guidance in sections 4.2 and 4.4. for cardiovascular status, growth, appetite, development of <em>de novo </em>or worsening of pre-existing psychiatric disorders. Psychiatric disorders to monitor for are described below, and include (but are not limited to) motor or vocal tics, aggressive or hostile behaviour, agitation, anxiety, depression, psychosis, mania, delusions, irritability, lack of spontaneity, withdrawal and excessive perseveration.</p><p><!--[if gte vml 1]><v:rect id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:241.25pt;
 margin-top:60.7pt;width:3.1pt;height:.7pt;z-index:-251658752;
 mso-position-horizontal-relative:page' fillcolor="black" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="4" height="1" src="file:///C:/Users/MAALAS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />The physician who elects to use methylphenidate for extended periods (over 12 months) in children and adolescents with ADHD should periodically re-evaluate the long-term usefulness of the medicinal product for the individual patient with trial periods off medication to assess the patient&#39;s functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the child&#39;s condition (preferably during times of school holidays). Improvement may be sustained when the medicinal product is either temporarily or permanently discontinued.</p><p><u>Use in adults</u></p><p>Safety and efficacy have not been established for the initiation of treatment in adults or the routine continuation of treatment beyond 18 years of age. If treatment withdrawal has not been successful when an adolescent has reached 18 years of age continued treatment into adulthood may be necessary. The need for further treatment of these adults should be reviewed regularly and undertaken annually.</p><p><u>Use in the elderly</u></p><p>Methylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group.</p><p>&nbsp;</p><p><u>Use in children under 6 years of age</u></p><p>Methylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.</p><p><u>Cardiovascular status</u></p><p>Patients who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden cardiac or unexplained death or malignant arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further specialist cardiac evaluation if initial findings suggest such history or disease. Patients who develop symptoms such as palpitations, exertional chest pain, unexplained syncope, dyspnoea or other symptoms suggestive of cardiac disease during methylphenidate treatment should undergo a prompt specialist cardiac evaluation.</p><p>Analyses of data from clinical trials of methylphenidate in children and adolescents with ADHD showed that patients using methylphenidate may commonly experience changes in diastolic and systolic blood pressure of over 10 mmHg relative to controls. The short- and long-term clinical consequences of these cardiovascular effects in children and adolescents are not known. The possibility of clinical complications cannot be excluded as a result of the effects observed in the clinical trial data especially when treatment during childhood/adolescence is continued into adulthood. <strong>Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate. </strong>See section 4.3 for conditions in which methylphenidate treatment in contraindicated.</p><p>Cardiovascular status should be carefully monitored. Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months.</p><p>The use of methylphenidate is contraindicated in certain pre-existing cardiovascular disorders <strong>unless specialist paediatric cardiac advice has been obtained (see section 4.3).</strong></p><p><em>Sudden death and pre-existing structural cardiac abnormalities or other serious cardiac disorders</em></p><p>Sudden death has been reported in association with the use of stimulants of the central nervous system at usual doses in children, some of whom had structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone may carry an increased risk of sudden death, stimulant products are not recommended in children or adolescents with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant medicine.</p><p><em>Misuse and cardiovascular events</em></p><p>Misuse of stimulants of the central nervous system may be associated with sudden death and other serious cardiovascular adverse events.</p><p><u>Cerebrovascular disorders</u></p><p>See section 4.3 for cerebrovascular conditions in which methylphenidate treatment is contraindicated. Patients with additional risk factors (such as a history of cardiovascular disease, concomitant medications that elevate blood pressure) should be assessed at every visit for neurological signs and symptoms after initiating treatment with methylphenidate.</p><p>Cerebral vasculitis appears to be a very rare idiosyncratic reaction to methylphenidate exposure. There is little evidence to suggest that patients at higher risk can be identified and the initial onset of symptoms may be the first indication of an underlying clinical problem. Early diagnosis, based on a high index of suspicion, may allow the prompt withdrawal of methylphenidate and early treatment. The diagnosis should therefore be considered in any patient who develops new neurological symptoms that are consistent with cerebral ischemia during methylphenidate therapy. These symptoms could include severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language or memory.</p><p>Treatment with methylphenidate is not contraindicated in patients with hemiplegic cerebral palsy. <u>Psychiatric disorders</u></p><p>Co-morbidity of psychiatric disorders in ADHD is common and should be taken into account when prescribing stimulant products. In the case of emergent psychiatric symptoms or exacerbation of pre-</p><p>&nbsp;</p><p>existing psychiatric disorders, methylphenidate should not be given unless the benefits outweigh the risks to the patient.</p><p>Development or worsening of psychiatric disorders should be monitored at every adjustment of dose, then at least every 6 months, and at every visit; discontinuation of treatment may be appropriate.</p><p><em>Exacerbation of pre-existing psychotic or manic symptoms</em></p><p>In psychotic patients, administration of methylphenidate may exacerbate symptoms of behavioural disturbance and thought disorder.</p><p><em>Emergence of new psychotic or manic symptoms</em></p><p>Treatment-emergent psychotic symptoms (visual/tactile/auditory hallucinations and delusions) or mania in children and adolescents without prior history of psychotic illness or mania can be caused by methylphenidate at usual doses. If manic or psychotic symptoms occur, consideration should be given to a possible causal role for methylphenidate, and discontinuation of treatment may be appropriate.</p><p><em>Aggressive or hostile behaviour</em></p><p>The emergence or worsening of aggression or hostility can be caused by treatment with stimulants. Aggression has been reported in patients treated with methylphenidate (see section 4.8). Patients treated with methylphenidate should be closely monitored for the emergence or worsening of aggressive behaviour or hostility at treatment initiation, at every dose adjustment and then at least every 6 months and every visit. Physicians should evaluate the need for adjustment of the treatment regimen in patients experiencing behaviour changes bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.</p><p><em>Suicidal tendency</em></p><p>Patients with emergent suicidal ideation or behaviour during treatment for ADHD should be evaluated immediately by their physician. Consideration should be given to the exacerbation of an underlying psychiatric condition and to a possible causal role of methylphenidate treatment. Treatment of an underlying psychiatric condition may be necessary and consideration should be given to a possible discontinuation of methylphenidate.</p><p><em>Tics</em></p><p>Methylphenidate is associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette&#39;s syndrome has also been reported. Family history should be assessed and clinical evaluation for tics or Tourette&#39;s syndrome in children should precede use of methylphenidate.</p><p>Patients should be regularly monitored for the emergence or worsening of tics during treatment with methylphenidate. <strong>Monitoring should be at every adjustment of dose and then at least every 6 months or every visit.</strong></p><p><em>Anxiety, agitation or tension</em></p><p>Anxiety, agitation and tension have been reported in patients treated with methylphenidate (see section 4.8). Methylphenidate is also associated with the worsening of pre-existing anxiety, agitation or tension, and anxiety led to discontinuation of methylphenidate in some patients. Clinical evaluation for anxiety, agitation or tension should precede use of methylphenidate and patients should</p><p>be regularly monitored for the emergence or worsening of these symptoms during treatment, at every adjustment of dose and then at least every 6 months or every visit.</p><p><em>Forms of bipolar disorder</em></p><p>Particular care should be taken in using methylphenidate to treat ADHD in patients with comorbid bipolar disorder (including untreated Type I Bipolar Disorder or other forms of bipolar disorder) because of concern for possible precipitation of a mixed/manic episode in such patients. Prior to initiating treatment with methylphenidate, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. <strong>Close ongoing monitoring is essential in these patients (see above &#39;Psychiatric Disorders&#39; and section 4.2). Patients should be monitored for symptoms at every adjustment of dose, then at least every 6 months and at every visit.</strong></p><p><u>Growth</u></p><p>&nbsp;</p><p>Moderately reduced weight gain and growth retardation have been reported with the long-term use of methylphenidate in children.</p><p>The effects of methylphenidate on final height and final weight are currently unknown and being studied.</p><p><strong>Growth should be monitored during methylphenidate treatment: height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart. </strong>Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.</p><p><u>Seizures</u></p><p>Methylphenidate should be used with caution in patients with epilepsy. Methylphenidate may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and rarely in patients without a history of convulsions and no EEG abnormalities. If seizure frequency increases or new-onset seizures occur, methylphenidate should be discontinued.</p><p><u>Priapism</u></p><p>Prolonged and painful erections have been reported in association with methylphenidate products, mainly in association with a change in the methylphenidate treatment regimen. Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.</p><p><u>Use with serotonergic medicinal products</u></p><p>Serotonin syndrome has been reported following coadministration of methylphenidate with serotonergic medicinal products. If concomitant use of methylphenidate with a serotonergic medicinal product is warranted, prompt recognition of the symptoms of serotonin syndrome is important. These symptoms may include mental-status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g. hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea). Methylphenidate must be discontinued as soon as possible if serotonin syndrome is suspected.</p><p><u>Abuse, misuse and diversion</u></p><p>Patients should be carefully monitored for the risk of diversion, misuse and abuse of methylphenidate.</p><p>Methylphenidate should be used with caution in patients with known drug or alcohol dependency because of a potential for abuse, misuse or diversion.</p><p>Chronic abuse of methylphenidate can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially in response to parenteral abuse.</p><p>Patient age, the presence of risk factors for substance use disorder (such as co-morbid oppositional- defiant or conduct disorder and bipolar disorder), previous or current substance abuse should all be taken into account when deciding on a course of treatment for ADHD. Caution is called for in emotionally unstable patients, such as those with a history of drug or alcohol dependence, because such patients may increase the dosage on their own initiative.</p><p>For some high-risk substance abuse patients, methylphenidate or other stimulants may not be suitable and non-stimulant treatment should be considered.</p><p><u>Withdrawal</u></p><p>Careful supervision is required during drug withdrawal, since this may unmask depression as well as chronic over-activity. Some patients may require long-term follow up.</p><p>Careful supervision is required during withdrawal from abusive use since severe depression may occur.</p><p><u>Fatigue</u></p><p>Methylphenidate should not be used for the prevention or treatment of normal fatigue states. <u>Excipients: galactose intolerance</u></p><p>&nbsp;</p><p>This medicinal product contains lactose: patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><u>Choice of methylphenidate formulation</u></p><p>The choice of formulation of methylphenidate-containing product will have to be decided by the treating specialist on an individual basis and depends on the intended duration of effect.</p><p><u>Drug screening</u></p><p>This product contains methylphenidate which may induce a false positive laboratory test for amphetamines, particularly with immunoassay screen test.</p><p><u>Renal or hepatic insufficiency</u></p><p>There is no experience with the use of methylphenidate in patients with renal or hepatic insufficiency. <u>Haematological effects</u></p><p>The long-term safety of treatment with methylphenidate is not fully known. In the event of leukopenia, thrombocytopenia, anaemia or other alterations, including those indicative of serious renal or hepatic disorders, discontinuation of treatment should be considered.</p><p><u>Potential for gastrointestinal obstruction</u></p><p>Because the Concentia tablet is nondeformable and does not appreciably change in shape in the gastrointestinal (GI) tract, it should not ordinarily be administered to patients with pre-existing severe GI narrowing (pathologic or iatrogenic) or in patients with dysphagia or significant difficulty in swallowing tablets. There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of drugs in nondeformable prolonged-release formulations.</p><p>Due to the prolonged-release design of the tablet, Concentia should only be used in patients who are able to swallow the tablet whole. Patients should be informed that Concentia must be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic interaction</u></p><p>It is not known how methylphenidate may effect plasma concentrations of concomitantly administered drugs. Therefore, caution is recommended at combining methylphenidate with other drugs, especially those with a narrow therapeutic window.</p><p>Methylphenidate is not metabolised by cytochrome P450 to a clinically relevant extent. Inducers or inhibitors of cytochrome P450 are not expected to have any relevant impact on methylphenidate pharmacokinetics. Conversely, the d- and l- enantiomers of methylphenidate do not relevantly inhibit cytochrome P450 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A.</p><p>However, there are reports indicating that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), and some antidepressants (tricyclics and selective serotonin reuptake inhibitors). When starting or stopping treatment with methylphenidate, it may be necessary to adjust the dosage of these drugs already being taken and establish drug plasma concentrations (or for coumarin, coagulation times).</p><p><u>Pharmacodynamic interactions</u></p><p><em>Anti-hypertensive drugs</em></p><p>Methylphenidate may decrease the effectiveness of drugs used to treat hypertension.</p><p><em>Use with drugs that elevate blood pressure</em></p><p>Caution is advised in patients being treated with methylphenidate with any other drug that can also elevate blood pressure (see also sections on cardiovascular and cerebrovascular conditions in section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Data from a cohort study of in total approximately 3,400 pregnancies exposed in the first trimester do not suggest an increased risk of overall birth defects. There was a small increased occurrence of cardiac malformations (pooled adjusted relative risk, 1.3; 95 % CI, 1.0-1.6) corresponding to 3 additional infants born with congenital cardiac malformations for every 1000 women who receive methylphenidate during the first trimester of pregnancy, compared with non-exposed pregnancies.</p><p>Cases of neonatal cardiorespiratory toxicity, specifically foetal tachycardia and respiratory distress have been reported in spontaneous case reports.</p><p>Studies in animals have shown evidence of reproductive toxicity at maternally toxic doses (see section 5.3).</p><p>Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy.</p><p><u>Breast-feeding</u></p><p>Methylphenidate is excreted in human milk. Based on reports of breast milk sampling from five mothers, methylphenidate concentrations in human milk resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage, and a milk to maternal plasma ratio ranging between 1.1 and 2.7.</p><p>There is one case report of an infant who experienced an unspecified decrease in weight during the period of exposure but recovered and gained weight after the mother discontinued treatment with methylphenidate. A risk to the suckling child cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from methylphenidate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There were no relevant effects observed in the non-clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methylphenidate can cause dizziness, drowsiness and visual disturbances including difficulties with accommodation, diplopia and blurred vision. It may have a moderate influence on the ability to drive and use machines. Patients should be warned of these possible effects and advised that if affected, they should avoid potentially hazardous activities such as driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The table below shows all adverse reactions observed during clinical trials of children, adolescents, and adults and post-market spontaneous reports with Concentia and those, which have been reported with other methylphenidate hydrochloride formulations. If the adverse reactions with Concentia and the methylphenidate formulation frequencies were different, the highest frequency of both databases was used.</p><p>Frequency estimate:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>(&ge; 1/10)</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>(&ge; 1/100 to &lt; 1/10)</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>(&ge; 1/1000 to &lt; 1/100)</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>(&ge; 1/10,000 to &lt; 1/1000)</p></td></tr><tr><td style="vertical-align:top"><p>very rare</p></td><td style="vertical-align:top"><p>(&lt; 1/10,000)</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>(cannot be estimated from the available data).</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>System Organ Class</p></td><td colspan="6" style="vertical-align:top"><p>Adverse Reaction</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Frequency</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nasopharyngitis, Upper respiratory tract infection#, Sinusitis#</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia&dagger;, Leucopenia&dagger;, Thrombo- cytopenia, Thrombo- cytopenic purpura</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions such as Angioneurotic oedema, Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritus, Rashes, and Eruptions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutritional disorders*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia, Decreased appetite&dagger;, Moderately reduced weight and height gain during prolonged use in children*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders*</p></td><td style="vertical-align:top"><p>Insomnia, Nervousness</p></td><td style="vertical-align:top"><p>Affect lability, Aggression*, Agitation*, Anxiety*&dagger;, Depression*#, Irritability, Abnormal behaviour, Mood swings, Tics*, Initial insomnia#, Depressed mood#, Libido decreased#,</p></td><td style="vertical-align:top"><p>Psychotic disorders*, Auditory, visual and tactile hallucination*, Anger, Suicidal ideation*, Mood altered, Restlessness&dagger;, Tearfulness, Worsening of pre-existing tics of Tourette&#39;s</p></td><td style="vertical-align:top"><p>Mania*&dagger;, Disorientation, Libido disorder, Confusional state&dagger;</p></td><td style="vertical-align:top"><p>Suicidal attempt (including completed suicide)* &dagger;, Transient depressed mood*, Abnormal thinking, Apathy&dagger;, Repetitive behaviours, Over-focussing</p></td><td style="vertical-align:top"><p>Delusions*&dagger;, Thought disturbances*, dependence. Cases of abuse and dependence have been described, more often with immediate release formulations</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tension#, Bruxism*, Panic attack# Psychiatric disorders</p></td><td style="vertical-align:top"><p>syndrome*, Logorrhoea, Hypervigilance, Sleep disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness,</p></td><td style="vertical-align:top"><p>Sedation,</p></td><td rowspan="20" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion,</p></td><td style="vertical-align:top"><p>Cerebrovascular</p></td></tr><tr><td style="vertical-align:top"><p>system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyskinesia,</p></td><td style="vertical-align:top"><p>Tremor&dagger;,</p></td><td style="vertical-align:top"><p>Choreo-athetoid</p></td><td style="vertical-align:top"><p>disorders*&dagger;(including</p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Psychomotor</p></td><td style="vertical-align:top"><p>Lethargy#</p></td><td style="vertical-align:top"><p>movements,</p></td><td style="vertical-align:top"><p>vasculitis, cerebral</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperactivity,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Reversible</p></td><td style="vertical-align:top"><p>haemorrhages,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ischaemic</p></td><td style="vertical-align:top"><p>cerebrovascular</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paresthaesia#,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>neurological</p></td><td style="vertical-align:top"><p>accidents, cerebral</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>deficit,</p></td><td style="vertical-align:top"><p>arteritis, cerebral</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>headache#</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neuroleptic</p></td><td style="vertical-align:top"><p>occlusion), Grand mal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>malignant</p></td><td style="vertical-align:top"><p>convulsion*,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>syndrome</p></td><td style="vertical-align:top"><p>Migraine,&dagger;Dysphemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(NMS; Reports</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>were poorly</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>documented and</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>in most cases,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>patients were</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>also receiving</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>other drugs, so</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>the role of</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>methylphenidate</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>is unclear).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Accommodation</p></td><td style="vertical-align:top"><p>Blurred vision&dagger;,</p></td><td style="vertical-align:top"><p>Difficulties in</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mydriasis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>disorder#</p></td><td style="vertical-align:top"><p>Dry eye#</p></td><td style="vertical-align:top"><p>visual</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>accommodation,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>impairment,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo#</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arrhythmia,</p></td><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>Cardiac arrest;</p></td><td style="vertical-align:top"><p>Supraventricular</p></td></tr><tr><td style="vertical-align:top"><p>disorders*</p></td><td style="vertical-align:top"><p>Tachycardia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial</p></td><td style="vertical-align:top"><p>tachycardia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>infarction</p></td><td style="vertical-align:top"><p>Bradycardia,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ventricular</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>extrasystoles&dagger;,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Extrasystoles&dagger;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Hot flush#</p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cerebral</p></td><td rowspan="7" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>disorders*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arteritis and/or</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>occlusion,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>coldness&dagger;,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Raynaud&#39;s</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>phenomenon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough,</p></td><td style="vertical-align:top"><p>Dyspnoea&dagger;</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>thoracic and</p></td><td style="vertical-align:top"><p>Oropharyngeal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>mediastinal</p></td><td style="vertical-align:top"><p>pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Gastro- intestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain upper, Diarrhoea, Nausea&dagger;, Abdominal discomfort, Vomiting, Dry mouth&dagger;, Dyspepsia#</p></td><td style="vertical-align:top"><p>Constipation&dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased#</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abnormal liver function, including acute hepatic failure and hepatic coma, Blood alkaline phosphatase increased, Blood bilirubin increased&dagger;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia, Pruritis, Rash, Urticaria, Hyperhidrosis</p></td><td style="vertical-align:top"><p>Angioneurotic oedema, Bullous conditions, Exfoliative conditions</p></td><td style="vertical-align:top"><p>Macular rash; Erythema</p></td><td style="vertical-align:top"><p>Erythema multiforme, Exfoliative dermatitis, Fixed drug eruption</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculo- skeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia, Muscle tightness#, Muscle spasms#</p></td><td style="vertical-align:top"><p>Myalgia&dagger;, Muscle twitching</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle cramps</p></td><td style="vertical-align:top"><p>Trismus*</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria, pollakiuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Incontinence</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction#</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Priapism*, Erection increased* and Prolonged erection*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site</p><p>conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia, Growth retardation during prolonged use in children*, Fatigue&dagger;, Irritability#, Feeling jittery#, Asthenia#, Thirst#</p></td><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sudden cardiac death*</p></td><td style="vertical-align:top"><p>Chest discomfort&dagger;, Hyperpyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Changes in blood pressure and heart rate (usually an increase)*, Weight decreased*</p></td><td style="vertical-align:top"><p>Cardiac murmur*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Platelet count decreased, White blood cell count abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp; See section 4.4</p><p># Frequency derived from adult clinical trials and not on data from trials in children and adolescents; may also be relevant for children and adolescents.</p><p>&dagger; Frequency derived from clinical trials in children and adolescent and reported at a higher frequency in clinical trials in adult patients.</p><p>*&nbsp; Based on the frequency calculated in adult ADHD studies (no cases were reported in the paediatric studies</p><p>*&nbsp; Based on the frequency calculated in adult ADHD studies (no cases were reported in the paediatric studies</p><p>*ADR from clinical trials in adult patients that was reported with a higher frequency than in children and adolescents</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Saudi Arabia:</p><p>The National Pharmacovigilance Centre (NPC). SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p>United Arab Emirates:</p><p>Pharmacovigilance &amp; Medical Device section P.O.Box: 1853 Tel: 80011111</p><p>Email : pv@mohap.gov.ae Drug Department</p><p>Ministry of Health &amp; Prevention, Dubai, UAE</p><p>&nbsp;</p><p>&nbsp;</p><p>Other GCC and Levant countries:</p><p>Please contact your doctor or pharmacist or nurse to report any side effect. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When treating patients with overdose, allowances must be made for the delayed release of methylphenidate from formulations with extended durations of action.</p><p><u>Signs and Symptoms</u></p><p>Acute overdose, mainly due to overstimulation of the central and sympathetic nervous systems, may result in vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes.</p><p><u>Treatment</u></p><p>&nbsp;</p><p>There is no specific antidote to methylphenidate overdosage. Treatment consists of appropriate supportive measures.</p><p>The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. The efficacy of activated charcoal has not been established.</p><p>Intensive care must be provided to maintain adequate circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia.</p><p>Efficacy of peritoneal dialysis or extracorporeal haemodialysis for overdose of methylphenidate has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: centrally acting sympathomimetics: ATC code: N06BA04 <u>Mechanism of action</u></p><p>Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space. Methylphenidate is a racemic mixture comprised of the d- and l-isomers. The d-isomer is more pharmacologically active than the l-isomer.</p><p><u>Clinical efficacy and safety</u></p><p>In the pivotal clinical studies, Methylphenidate was assessed in 321 patients already stabilised with immediate release preparations (IR) of methylphenidate and in 95 patients not previously treated with IR preparations of methylphenidate.</p><p>Clinical studies showed that the effects of Methylphenidate were maintained until 12 hours after dosing when the product was taken once daily in the morning.</p><p>Eight hundred ninety-nine (899) adults with ADHD aged 18 to 65 years were evaluated in three double-blind, placebo-controlled studies of 5 to 13 weeks duration. Some short-term efficacy has been demonstrated for Methylphenidate in a dosage range of 18 to 72 mg/day, but this has not been consistently shown beyond 5 weeks. In one study, in which response was defined as at least a 30% reduction from baseline in Conners&#39; Adult ADHD Rating Scales (CAARS) ADHD Symptoms total score at Week 5 (endpoint) and analysed assuming subjects with missing data at their final visit were non-responders, a significantly higher proportion of patients responded to treatment with Methylphenidate at doses of 18, 36, or 72 mg/day compared to placebo. In the two other studies, when analysed assuming subjects with missing data at their final visit were non-responders, there were numerical advantages for Methylphenidate compared to placebo but a statistically significant difference in the proportion of patients meeting predefined response criteria was not demonstrated between Methylphenidate and placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Methylphenidate is readily absorbed. Following oral administration of Methylphenidate to adults the drug overcoat dissolves, providing an initial maximum drug concentration at about 1 to 2 hours. The methylphenidate contained in the two internal drug layers is gradually released over the next several hours. Peak plasma concentrations are achieved at about 6 to 8 hours, after which plasma levels of methylphenidate gradually decrease. Methylphenidate taken once daily minimises the fluctuations between peak and trough concentrations associated with immediate-release methylphenidate three times daily. The extent of absorption of Methylphenidate once daily is generally comparable to conventional immediate release preparations.</p><p>Following the administration of Methylphenidate 18 mg once daily in 36 adults, the mean pharmacokinetic&nbsp;parameters were: Cmax&nbsp; 3.7&nbsp;&plusmn; 1.0 (ng/mL), Tmax&nbsp; 6.8&nbsp;&plusmn; 1.8 (h), AUCinf&nbsp; 41.8&nbsp;&plusmn; 13.9 (ng.h/mL), and t&frac12;&nbsp;&nbsp; 3.5&nbsp;&plusmn; 0.4 (h).</p><p>No differences in the pharmacokinetics of Methylphenidate were noted following single and repeated once&nbsp;daily dosing, indicating no significant drug accumulation. The AUC and t1/2&nbsp; following&nbsp;repeated once daily dosing are similar to those following the first dose of Methylphenidate 18 mg.</p><p>Following administration of Methylphenidate in single doses of 18, 36, and 54 mg/day to adults, Cmax&nbsp;&nbsp; and&nbsp;AUCinf&nbsp;&nbsp; of&nbsp;methylphenidate were proportional to dose.</p><p><u>Distribution</u></p><p>Plasma methylphenidate concentrations in adults decline biexponentially following oral administration. The half-life of methylphenidate in adults following oral administration of Methylphenidate was approximately 3.5 h. The rate of protein binding of methylphenidate and of its</p><p>&nbsp;</p><p>metabolites is approximately 15%. The apparent volume of distribution of methylphenidate is approximately 13 litres/kg.</p><p><u>Biotransformation</u></p><p>In humans, methylphenidate is metabolised primarily by de-esterification to alpha-phenyl-piperidine acetic acid (PPA, approximately 50 fold the level of the unchanged substance) which has little or no pharmacologic activity. In adults the metabolism of Methylphenidate once daily as evaluated by metabolism to PPA is similar to that of methylphenidate three times daily. The metabolism of single and repeated once daily doses of Methylphenidate is similar.</p><p><u>Elimination</u></p><p>The elimination half-life of methylphenidate in adults following administration of Methylphenidate was approximately 3.5 hours. After oral administration, about 90% of the dose is excreted in urine and 1 to 3% in faeces, as metabolites within 48 to 96 hours. Small quantities of unchanged methylphenidate are recovered in urine (less than 1%). The main urinary metabolite is alpha-phenyl- piperidine acetic acid (60-90%).</p><p>After oral dosing of radiolabelled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was PPA, accounting for approximately 80% of the dose.</p><p><u>Food Effects</u></p><p>In patients, there were no differences in either the pharmacokinetics or the pharmacodynamic performance of Methylphenidate when administered after a high fat breakfast on an empty stomach.</p><p><u>Special Populations</u></p><p><em>Gender</em></p><p>In&nbsp;healthy adults, the mean dose-adjusted AUCinf&nbsp; values&nbsp;for Methylphenidate were 36.7 ng.h/mL in men and 37.1 ng.h/mL in women, with no differences noted between the two groups.</p><p><em>Race</em></p><p>In&nbsp;healthy adults receiving Methylphenidate, dose-adjusted AUCinf&nbsp; was&nbsp;consistent across ethnic groups; however, the sample size may have been insufficient to detect ethnic variations in pharmacokinetics.</p><p><em>Age</em></p><p>The pharmacokinetics of Methylphenidate has not been studied in children younger than 6 years of age. In children 7-12 years of age, the pharmacokinetics of Methylphenidate after 18, 36 and 54 mg were&nbsp;(mean&plusmn;SD): Cmax 6.0&nbsp;&plusmn; 1.3, 11.3 &plusmn; 2.6, and 15.0 &plusmn; 3.8 ng/mL, respectively, Tmax&nbsp; 9.4&nbsp;&plusmn; 0.02, 8.1 &plusmn;</p><p>1.1,&nbsp;9.1&nbsp;&plusmn;&nbsp;2.5&nbsp;h,&nbsp;respectively,&nbsp;and&nbsp;AUC0-11.5&nbsp; 50.4&nbsp;&plusmn;&nbsp;7.8,&nbsp;87.7&nbsp;&plusmn;&nbsp;18.2,&nbsp;121.5&nbsp;&plusmn;&nbsp;37.3&nbsp;ng.h/mL,</p><p>respectively.</p><p><em>Renal Insufficiency</em></p><p>There is no experience with the use of Methylphenidate in patients with renal insufficiency. After oral administration of radiolabelled methylphenidate in humans, methylphenidate was extensively metabolised and approximately 80% of the radioactivity was excreted in the urine in the form of PPA. Since renal clearance is not an important route of methylphenidate clearance, renal insufficiency is expected to have little effect on the pharmacokinetics of Methylphenidate.</p><p><em>Hepatic Insufficiency</em></p><p>There is no experience with the use of Methylphenidate in patients with hepatic insufficiency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenicity</u></p><p>In life-time rat and mouse carcinogenicity studies, increased numbers of malignant liver tumours were noted in male mice only. The significance of this finding to humans is unknown.</p><p>&nbsp;</p><p>Methylphenidate did not affect reproductive performance or fertility at low multiples of the clinical dose.</p><p><u>Pregnancy-embryonal/foetal development</u></p><p>Methylphenidate is not considered to be teratogenic in rats and rabbits. Foetal toxicity (i.e. total litter loss) and maternal toxicity was noted in rats at maternally toxic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypromellose</p><p>Macrogol (Polyethylene Oxide) Succinic Acid</p><p>Magnesium Stearate Sodium Chloride</p><p>Silica colloidal, anhydrous Black Iron Oxide</p><p>&nbsp;</p><p><u>Film coating</u> Cellullose Acetate Macrogol</p><p>&nbsp;</p><p><u>Clear coating</u> Hypromellose Macrogol Phosphoric Acid</p><p>&nbsp;</p><p><u>Color coating</u> Lactose Monohydrate Hypromellose Titanium dioxide Triacetin</p><p>Yellow Iron Oxide Red Iron Oxide Lactose Monohydrate Ferrosoferric Oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years

In use: 30 days

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the bottle tightly closed to protect from moisture Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product would be packaged in HDPE bottle including 2 canisters with child resistant cap.</p><p>&nbsp;</p><p>Pack size: 30 prolonged release tablet; 60 prolonged release tablet (2x30) and 90 prolonged release tablet (3x30)</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Exeltis Healthcare S.L.
Pol. Ind. Miralcampo. Avda. Miralcampo, 7. 19200 Azuqueca de Henares. Guadalajara Spain

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>